Skip to main content

Wagner Charles F Jr's Form 4 filing

Vertex Pharmaceuticals Inc (VRTX) · filed Feb 3, 2022

Accession no.
0001209191-22-006796
Filed
Feb 3, 2022
Trade date
Feb 1-2, 2022
Filing delay
2 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 4 non-derivative transactions. Open-market sales total $736.2K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Wagner Charles F JrCIK 0001223348Officer (EVP & Chief Financial Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Feb 1, 2022Common StockAGrant or awardAcquired+3,698$0.00$038,489Direct
Feb 1, 2022Common StockAGrant or awardAcquired+11,628$0.00$050,117Direct
Feb 1, 2022Common StockAGrant or awardAcquired+10,262$0.00$060,379Direct
Feb 2, 2022Common StockSSaleDisposed−2,944$250.07F5,F6−$736,206.0857,435Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F5

Open market sales reported on this line occurred at a weighted average price of $250.07 (range $250.00 to $250.09).

Referenced by the price of 1 transaction in Table I.

F6

Mr. Wagner undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

Referenced by the price of 1 transaction in Table I.

Remarks

Exhibit 24 - Power of Attorney

Read the full filing on SEC EDGAR (opens in a new tab)